Almac expands neo-antigen peptide manufacturing

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Oatawa)
(Image: Getty/Oatawa)

Related tags: Peptide, Manufacturing, Cancer, Gmp, Almac, Almac group, Supply chain

Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.

Almac Group, a contract development and manufacturing organization (CDMO), added a second stream for high throughput good manufacturing practice (GMP) peptide manufacture to its facility in Edinburgh, Scotland. The site manufactures neo-antigen derived peptides for the production of its individualized cancer vaccines, NeoPeptides.

The Edinburgh facility, according to the company, has a track record of high-speed peptide manufacturing, and its second line has been built upon these standards of speed. A recent increase in demand for Almac’s peptides served as the driving force behind developing a second GMP manufacturing line.

Charles Shields, vice president of peptides and small molecule active pharmaceutical ingredient (API) division, stated in a press release, that the company’s expansion is a reflection of its market understanding and its intention to maintain its worldwide supply position.

Over 80 GMP peptides were manufactured and released by the company in the first eight weeks of GMP operation at the facility, according to Almac.

Shields added that further developments of the facility and in service offerings are forthcoming.

Almac also recently worked on its supply position after expanding​ its commercial packaging capabilities – following demand for more sterile biological products on the market.

Related news

Related products

show more

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers

Follow us

Products

View more